nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-179-7-4-51nogr-1395Research ArticleРЕКОМЕНДАЦИИ НОГР (Научного общества гастроэнтерологов России) и РМНОТGUIDELINES AND RECOMMENDATIONS FOR PHYSICIANSВедение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Научного общества гастроэнтерологов РоссииManagement of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of RussiaГриневичВ. Б.GrinevichV. B.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

КравчукЮ. А.KravchukYu. A.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

ПедьВ. И.PedV. I.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

СасЕ. И.SasE. I.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

СаликоваС. П.SalikovaS. P.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

ГубонинаИ. В.GuboninaI. V.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

ТкаченкоЕ. И.TkachenkoE. I.

194044, Санкт-Петербург, улица Академика Лебедева, д. 6.

194044, St. Petersburg, Akademika Lebedev street, 6.

СиткинС. И.SitkinS. I.

197110, Санкт-Петербург, ул. Пудожская, д. 7; 197341, Санкт-Петербург, ул. Аккуратова, д. 2; 191015, Санкт-Петербург, Кирочная ул., 41.

197110, St. Petersburg, Pudozhskaya St., 7; 197341, St. Petersburg, Akkuratova St., 2; 191015, St. Petersburg, Kirochnaya street, 41.

ЛазебникЛ. Б.LazebnikL. B.

127473, Москва, ул. Делегатская, д. 20, стр.1.

127473, Moscow, Delegatskaya St., 20, p. 1.

ГоловановаЕ. В.GolovanovaE. V.

127473, Москва, ул. Делегатская, д. 20, стр.1.

127473, Moscow, Delegatskaya St., 20, p. 1.

Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской ФедерацииРоссияMilitary Medical Academy named after S.M. KirovRussian FederationГосударственный научно-исследовательский институт особо чистых биопрепаратов Федерального медико-биологического агентства; Национальный медицинский исследовательский центр имени В.А. Алмазова Министерства здравоохранения Российской Федерации; Северо-Западный государственный медицинский университет им. И.И. Мечникова Министерства здравоохранения Российской ФедерацииРоссияState Research Institute of Highly Pure Biopreparations of FMBA of Russia; Almazov National Medical Research Centre; North-Western state medical University named after I.I. Mechnikov, Ministry of health of the Russian FederationRussian FederationМосковский государственный медико-стоматологический университет имени А.И. Евдокимова Министерства здравоохранения Российской ФедерацииРоссияFSBEI HE MGMSU named after A.I. Yevdokimov of the Ministry of Health of RussiaRussian Federation20202609202007451Copyright © Гриневич В.Б., Кравчук Ю.А., Педь В.И., Сас Е.И., Саликова С.П., Губонина И.В., Ткаченко Е.И., Ситкин С.И., Лазебник Л.Б., Голованова Е.В., 20202020Гриневич В.Б., Кравчук Ю.А., Педь В.И., Сас Е.И., Саликова С.П., Губонина И.В., Ткаченко Е.И., Ситкин С.И., Лазебник Л.Б., Голованова Е.В.Grinevich V.B., Kravchuk Y.A., Ped V.I., Sas E.I., Salikova S.P., Gubonina I.V., Tkachenko E.I., Sitkin S.I., Lazebnik L.B., Golovanova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1395

В представленных клинических рекомендациях Научного общества гастроэнтерологов России (НОГР) рассмотрены основные профилактические и лечебно-диагностические подходы к ведению пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Рекомендации утверждены XXIII съездом НОГР и 22-м Международным Славяно-Балтийским научным форумом «Санкт-Петербург — Гастро-2020 ON-LINE» (Санкт-Петербург, 11 июня 2020 года).

The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientific Forum “St. Petersburg — Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020).

COVID-19COVID-19ReferencesMao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. doi:10.1016/S2468-1253(20)30126-6Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1):e000417. doi:10.1136/bmjgast-2020-000417Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1):e000417. doi:10.1136/bmjgast-2020-000417Cheung K.S., Hung I. F., Chan P. P. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. -2020 Apr 3: S0016-5085(20)30448-0. doi: 10.1053/j.gastro.2020.03.065.Cheung K.S., Hung I. F., Chan P. P. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. -2020 Apr 3: S0016-5085(20)30448-0. doi: 10.1053/j.gastro.2020.03.065.Sultan S., Altayar O., Siddique S. M. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. - 2020. -May 11: S0016-5085(20)30593-X. doi: 10.1053/j.gastro.2020.05.001.Sultan S., Altayar O., Siddique S. M. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. - 2020. -May 11: S0016-5085(20)30593-X. doi: 10.1053/j.gastro.2020.05.001.Parasa S, Desai M, Th oguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(6):e2011335. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.11335Parasa S, Desai M, Th oguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(6):e2011335. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.11335Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;(29):7-15. doi:10.1093/oxfordjournals.jncimonographs.a003443Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;(29):7-15. doi:10.1093/oxfordjournals.jncimonographs.a003443Захаров А.А., Ильна Н. А. Анализ микрофлоры ротовой полости обследованных людей с различными заболеваниями // Успехи современного естествознания. - 2007, № 12 (приложение, часть 3). - С. 141-143.Zakharov A. A., Ilna N. A. Analysis of the oral microflora of the examined people with various diseases. Advances in current natural sciences. 2007, No. 12 (part 3), pp. 141143.AADR PRESS RELEASES. Journal of Dental Research Systematic Analysis Examines Global Burden of Oral Conditions. Available at: https://www.iadr.org/AADR/About-Us/News/ArtMID/134369/ArticleID/338/Journal-of-Dental-Research-Systematic-Analysis-Examines-Global-Burden-of-Oral-Conditions (Monday, March 20, 2017)AADR PRESS RELEASES. Journal of Dental Research Systematic Analysis Examines Global Burden of Oral Conditions. Available at: https://www.iadr.org/AADR/About-Us/News/ArtMID/134369/ArticleID/338/Journal-of-Dental-Research-Systematic-Analysis-Examines-Global-Burden-of-Oral-Conditions (Monday, March 20, 2017)Risk Factors. Available at: https://www.fdiworlddental.org/oral-health/risk-factors. [Accessed 10 August 2020].Risk Factors. Available at: https://www.fdiworlddental.org/oral-health/risk-factors. [Accessed 10 August 2020].Xu H., Zhong L., Deng J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. - 2020. - Vol. 12, Iss. 8Xu H., Zhong L., Deng J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. - 2020. - Vol. 12, Iss. 8Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24(4):1619-1621. doi:10.1007/s00784-020-03248-xSabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24(4):1619-1621. doi:10.1007/s00784-020-03248-xXiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020;26(8):1920-1922. doi:10.3201/eid2608.200681Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020;26(8):1920-1922. doi:10.3201/eid2608.200681Arimura H. Effect of lysozyme from human placenta on ectromelia virus. Acta Virol. 1973;17(2):130-137.Arimura H. Effect of lysozyme from human placenta on ectromelia virus. Acta Virol. 1973;17(2):130-137.Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mo-sapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121-124.Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mo-sapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121-124.Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter Pylori заболеваний VI Московские соглашения. Экспериментальная и клиническая гастроэнтерология. - 2017. - № 138 (2). - С. 3-21.Lazebnik L. B., Tkachenko E. I., Abdulganiyeva D. I., et al, Yakovenko E. P. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter Pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3-21. (In Russ.)Ивашкин В.Т., Маев И. В., Трухманов А. С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальнойрефлюксной болезни. Рос журнгастроэнтеролгепатолколопроктол. - 2017. -№ 27(4). - С. 75-95.Ivashkin V. T., Mayev I. V., A. s. Trukhmanov I., et al. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75-95. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-75-95Гриневич В.Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. - 2020. - № 176 (4). DOI:10.31146/1682-8658-ecg-176-4Grinevich V. B., Kravchuk Yu. A., et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020;174(4):3-18. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-176-4-3-18Временные методические рекомендации МЗ РФ. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020). - 165 c.Temporary guidelines of the Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Moscow. Version 7 (03/06/2020), 165 p.Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. Published 2019 May 8. doi:10.1371/journal.pone.0216750Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. Published 2019 May 8. doi:10.1371/journal.pone.0216750Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. - 2017. - Vol. 3(11): eaao4966. Published 2017 Nov 15. doi:10.1126/sciadv.aao4966.Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. - 2017. - Vol. 3(11): eaao4966. Published 2017 Nov 15. doi:10.1126/sciadv.aao4966.World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics'. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiot-ics-and-prebiotics-english [Accessed 10 August 2020].World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics'. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiot-ics-and-prebiotics-english [Accessed 10 August 2020].Гриневич, В. Б. Пребиотическая коррекция микробно-тканевого комплекса кишечника, как базовая составляющая современной патогенетической терапии метаболического синдрома и ассоциированных кардиоваскулярных и цереброваскулярных заболеваний. Учебно-методическое пособие / В. Б. Гриневич, Е. И. Сас, В. Е. Кон [и др.]. - СПб., 2012. - 20 с.Grinevich VB, Sas VE, Kon, et al. Prebiotic correction of the intestinal microbial-tissue complex as a basic component of modern pathogenetic therapy of metabolic syndrome and associated cardiovascular and cerebrovascular diseases. Study guide. SPb., 2012, 20 P.Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?. Aliment Pharmacol Ther. 2005;22(2):79-94. doi:10.1111/j.1365-2036.2005.02531.xFass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?. Aliment Pharmacol Ther. 2005;22(2):79-94. doi:10.1111/j.1365-2036.2005.02531.xHong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-916. doi:10.5009/gnl15537Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-916. doi:10.5009/gnl15537Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393-3398. doi:10.1007/s10620-010-1166-9Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393-3398. doi:10.1007/s10620-010-1166-9Wen X., Chen X., Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. 2009;34(5):457-160.Wen X., Chen X., Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. 2009;34(5):457-160.Yasuda T, Chiba H, Satomi T, et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4):e3. Published 2012 Jan 1. doi:10.5037/jomr.2011.2403Yasuda T, Chiba H, Satomi T, et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4):e3. Published 2012 Jan 1. doi:10.5037/jomr.2011.2403Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2Jiang G, Cai Y, Yi X, et al. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study [published online ahead of print, 2020 May 12]. J Med Virol. 2020;10.1002/jmv.25998. doi:10.1002/jmv.25998Jiang G, Cai Y, Yi X, et al. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study [published online ahead of print, 2020 May 12]. J Med Virol. 2020;10.1002/jmv.25998. doi:10.1002/jmv.25998Lechien JR, Bartaire E, Bobin F, Hans S, Saussez S. The association between laryngopharyngeal reflux and COVID-19 is still not demonstrated [published online ahead of print, 2020 May 28]. J Med Virol. 2020; doi:10.1002/jmv.26080Lechien JR, Bartaire E, Bobin F, Hans S, Saussez S. The association between laryngopharyngeal reflux and COVID-19 is still not demonstrated [published online ahead of print, 2020 May 28]. J Med Virol. 2020;10.1002/jmv.26080. doi:10.1002/jmv.26080Matysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 Suppl 1:55-62. doi:10.1046/j.1365-2036.18.s1.6.xMatysiak-Budnik T, Heyman M, Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 Suppl 1:55-62. doi:10.1046/j.1365-2036.18.s1.6.xShim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;329:40-47. doi:10.1016/j.taap.2017.05.012Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;329:40-47. doi:10.1016/j.taap.2017.05.012Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi:10.1007/s10620-017-4871-9Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi:10.1007/s10620-017-4871-9Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259-263. doi:10.1089/jop.2011.0142Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259-263. doi:10.1089/jop.2011.0142Matsuda T, Ohno S, Hirohata S, et al. Efficacy of re-bamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi:10.2165/00126839-200304010-00002Matsuda T, Ohno S, Hirohata S, et al. Efficacy of re-bamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi:10.2165/00126839-200304010-00002Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журнгастроэнтеролгепатолколо-проктол. - 2019. - Т. 29, № 5. - С. 53-74. https://doi.org/10.22416/1382-4376-2019-29-5-53-74Ivashkin V. T., Mayev I. V., Kaprin A. D., et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53-74. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-5-53-74Мартынов А. И., Шептулин А. А., Маев И. В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Рос журнгастроэнтеролгепатолколопроктол. - 2020. Т. 30, № 2. - С. 7-14. https://doi.org/10.22416/1382-4376-2020-30-2-7-14Martynov A. I., Sheptulin A. A., Mayev I. V., et al. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-14. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-2-7-14Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacterpylori у взрослых. Рос журнгастроэнтеролгепатолколопроктол. - 2018. - Т. 28, № 1. - С. 55-70. https://doi.org/10.22416/1382-4376-2018-28-1-55-70Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-1-55-70Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. doi:10.1159/000452356Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. doi:10.1159/000452356Simadibrata M. et al. Anti free radical &anti inflammatory effect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013, - Vol. 3, pp. 72-77.Simadibrata M. et al. Anti free radical &anti inflammatory effect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013, - Vol. 3, pp. 72-77.Hayashi S, Sugiyama T, Amano K, et al. Effect of re-bamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. doi:10.1128/AAC.42.8.1895Hayashi S, Sugiyama T, Amano K, et al. Effect of re-bamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. doi:10.1128/AAC.42.8.1895Симаненков В. И., Бакулина Н. В., Филь Т. С., Хубиева А. Х. Оценка эффективности эрадикации Н. Pylori при добавлении к схеме лечения цитопро-тективного препарата ребамипид: результаты исследования Бастион. Фарматека. - 2017. - S5. - C. 65-70.Simanenkov V. I., Bakulina N. V., Fil Т. S., Khubieva A. Kh. Evaluation of efficiency of H. Pylori eradication in case of addition of cytoprotective preparation rebamipide to the treatment: results of the bastion trial. Farmateka. 2017:S5;65-70.Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. Published 2019 Sep 19. doi:10.3390/jcm8091498Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. Published 2019 Sep 19. doi:10.3390/jcm8091498Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Лечение инфекции Helicobacterpylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Рос журнгастроэнтеролгепатолколопроктол. - 2017. - Т. 27, № 4. - С. 4-21.Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4-21. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-4-21Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-XXu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-XXia L., Wu K. Gastroenterology Practice in COVID-19 Epidemic. World Gastroenterology News. May 2020. pp. 7-10Xia L., Wu K. Gastroenterology Practice in COVID-19 Epidemic. World Gastroenterology News. May 2020. pp. 7-10Consensus of Diagnosis and Treatment of digestive disorders related to COVID-19. Natl Med J Chin. - 2020. - Vol. 40: E001. Published OnlineConsensus of Diagnosis and Treatment of digestive disorders related to COVID-19. Natl Med J Chin. - 2020. - Vol. 40: E001. Published OnlineCha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-2332. doi:10.3748/wjg.v26.i19.2323Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-2332. doi:10.3748/wjg.v26.i19.2323Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. -2018. - № 56. - С. 1-29.Karateev A. E., Nasonov E. L., Ivashkin V. T., et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. - 2018. - № 151(03). - С. 04-18.Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinflammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;(3):4-18. (In Russ.)Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518-1519. doi:10.1053/j.gastro.2020.02.054Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518-1519. doi:10.1053/j.gastro.2020.02.054Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J Hepatol. - 2020; S0168-8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J Hepatol. - 2020; S0168-8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewarticle/926628Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewarticle/926628Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. doi: 10.1111/LIV.14470Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. doi: 10.1111/LIV.14470Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6. doi:10.1016/j.cell.2020.02.058Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6. doi:10.1016/j.cell.2020.02.058Chai X., Hu L., Zhang Y. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. 02.03.931766.Chai X., Hu L., Zhang Y. et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv. 02.03.931766.Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-1796. doi:10.1136/gut.2004.062398Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-1796. doi:10.1136/gut.2004.062398Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113Fan Z., Chen L., Li J., Tian C., Zhang Y., Huang S. et al. Clinical Features of COVID-19-Related Liver Damage. -2020. Available at SSRN3546077. DOI: 10.2139/ssrn.3546077.Fan Z., Chen L., Li J., Tian C., Zhang Y., Huang S. et al. Clinical Features of COVID-19-Related Liver Damage. -2020. Available at SSRN3546077. DOI: 10.2139/ssrn.3546077.Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507-13.Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 2020; 395(10223): 507-13.Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144-1145. doi:10.1136/gutjnl-2020-321051Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144-1145. doi:10.1136/gutjnl-2020-321051Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3Guan W. J., Ni Z.Y, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020; NEJMoa2002032. doi:10.1056/NEJMoa2002032Guan W. J., Ni Z.Y, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020; NEJMoa2002032. doi:10.1056/NEJMoa2002032Albillos A., Lario M., Alvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385-1396.Albillos A., Lario M., Alvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology 2014;61:1385-1396.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-XXu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-XLi X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/S0140-6736(20)30628-0Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. doi:10.1111/liv.14435Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. doi:10.1111/liv.14435Zhang C., Shi L., Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper 17Zhang C., Shi L., Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterology & Hepatology 2020. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper 17Gao F. et al. Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic PatientsJ Gastroenterol Hepatol. - 2020. doi: 10.1111/jgh.15112.Gao F. et al. Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic PatientsJ Gastroenterol Hepatol. - 2020. doi: 10.1111/jgh.15112.Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705-708. doi:10.1016/j.jhep.2020.05.013Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705-708. doi:10.1016/j.jhep.2020.05.013Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi:10.1056/NEJMp2003539Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi:10.1056/NEJMp2003539Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451-458. doi:10.4065/mcp.2009.0534Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451-458. doi:10.4065/mcp.2009.0534Маевская М. В., Надинская М. Ю., Луньков В. Д. и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2019. - Т. 29(6). - С. 22-29.Mayevskaya M. V., Nadinskaia M. Yu., Lunkov V. D., et al. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) https://doi.org/10.22416/1382-4376-2019-29-6-22-29Mroz MS, Harvey BJ. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids. 2019;151:108461. doi:10.1016/j.steroids.2019.108461Mroz MS, Harvey BJ. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells. Steroids. 2019;151:108461. doi:10.1016/j.steroids.2019.108461Schultz F, Hasan A, Alvarez-Laviada A, et al. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. Prog Biophys Mol Biol. 2016;120(1-3):149-163. doi:10.1016/j.pbiomolbio.2016.01.003Schultz F, Hasan A, Alvarez-Laviada A, et al. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. Prog Biophys Mol Biol. 2016;120(1-3):149-163. doi:10.1016/j.pbiomolbio.2016.01.003Işık S, Karaman M, Qilaker Micili S, et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017;45(4):339-349. doi:10.1016/j.aller.2016.12.003Işık S, Karaman M, Qilaker Micili S, et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017;45(4):339-349. doi:10.1016/j.aller.2016.12.003Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019;234(11):20057-20065. doi:10.1002/jcp.28602Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxycholic acid stimulates alveolar fluid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019;234(11):20057-20065. doi:10.1002/jcp.28602Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published 2020 Jun 19. doi:10.3390/vaccines8020320Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published 2020 Jun 19. doi:10.3390/vaccines8020320Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm [published online ahead of print, 2020 May 30]. Med Hypotheses. 2020;143:109897. doi:10.1016/j.mehy.2020.109897Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm [published online ahead of print, 2020 May 30]. Med Hypotheses. 2020;143:109897. doi:10.1016/j.mehy.2020.109897Hoff mann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell - 2020. - Vol. 181. - P. 271-280.Hoff mann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell - 2020. - Vol. 181. - P. 271-280.Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. - 2020. -Vol. 5. - P. 562-569.Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. - 2020. -Vol. 5. - P. 562-569.Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. - 2020. - Vol. 69(6). - P. 997-1001. doi: 10.1136/gutjnl-2020-321013.Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. - 2020. - Vol. 69(6). - P. 997-1001. doi: 10.1136/gutjnl-2020-321013.Estes M. K. G., Knipe D. M., Howley P. M. et al. Rotaviruses, in Fields Virology (Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013), 6th ed., pp. 1347-1401.Estes M. K. G., Knipe D. M., Howley P. M. et al. Rotaviruses, in Fields Virology (Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013), 6th ed., pp. 1347-1401.Zang R., Gomez Castro M. F., McCune B.T. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. - 2020. - Vol. 5(47): eabc3582. doi:10.1126/sciimmunol.abc3582Zang R., Gomez Castro M. F., McCune B.T. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. - 2020. - Vol. 5(47): eabc3582. doi:10.1126/sciimmunol.abc3582Marild K., Fredlund H., Ludvigsson J. F. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. The American journal of gastroenterology. - 2010. - Vol. 105(11). - P. 2465-2473Marild K., Fredlund H., Ludvigsson J. F. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. The American journal of gastroenterology. - 2010. - Vol. 105(11). - P. 2465-2473Di Sabatino A. Is it worth investigating splenic function in patients with celiac disease? World journal of gastroenterology: WJG. - 2013. - Vol. 19(15). - P. 2313Di Sabatino A. Is it worth investigating splenic function in patients with celiac disease? World journal of gastroenterology: WJG. - 2013. - Vol. 19(15). - P. 2313Altamimi E. Effect of COVID-19 Pandemic and Lockdown on Children With Gastrointestinal Disorders // Gastroenterology Research. - 2020Altamimi E. Effect of COVID-19 Pandemic and Lockdown on Children With Gastrointestinal Disorders // Gastroenterology Research. - 2020Al-Toma A., Volta U., Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. - 2019 - Vol. 7(5). -P. 583-613. doi: 10.1177/2050640619844125.Al-Toma A., Volta U., Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. - 2019 - Vol. 7(5). -P. 583-613. doi: 10.1177/2050640619844125.Лазебник Л. Б., Ткаченко Е. И., Орешко Л. С. и др. рекомендации по диагностике и лечению целиакии взрослых Экспериментальная и клиническая гастроэнтерология - 2015. - № 117 (5). - Р. 3-12Lazebnik LB, Tkachenko YI, Oreshko LS, et al. Guidelines for diagnosis and treatment of celiac disease. Eksp Klin Gastroenterol. 2015;(5):3-12.Siniscalchi M. et al. COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine: COVID-19 and CeD // Digestive and Liver Disease. - 2020Siniscalchi M. et al. COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine: COVID-19 and CeD // Digestive and Liver Disease. - 2020Lee A. R. Telehealth Counseling for Patients with Celiac Disease During COVID-19 //Gastroint Hepatol Dig Dis. - 2020. - Т. 3. - № . 1. - С. 1-2.Lee A. R. Telehealth Counseling for Patients with Celiac Disease During COVID-19 //Gastroint Hepatol Dig Dis. - 2020. - Т. 3. - № . 1. - С. 1-2.Ивашкин В. Т., Шелыгин Ю. А. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. - 2017. - № 2. - С. 7-29.Article E. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of crohn's disease. Koloproktologia. 2017;(2):7-29. (In Russ.) https://doi.org/10.33878/2073-7556-2017-0-2-7-29Goldstein J. L., Eisen G. M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment PharmacolTher. - 2007. - Vol. 15; 25(10). - P. 1211-22.Goldstein J. L., Eisen G. M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment PharmacolTher. - 2007. - Vol. 15; 25(10). - P. 1211-22.Washio E., Esaki M., Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal AntiInflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. - 2016. Vol. 14(6). - P. 809-15.Washio E., Esaki M., Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal AntiInflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. - 2016. Vol. 14(6). - P. 809-15.Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate to severe small intestinal damage. PLoS One. - 2015. - Vol. 10(4): e0122330Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate to severe small intestinal damage. PLoS One. - 2015. - Vol. 10(4): e0122330Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. - 2013. - Vol. 58(7). - P. 1991-2000.Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. - 2013. - Vol. 58(7). - P. 1991-2000.Massironi S., Vigano C., Dioscoridi L. et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol. -2020 May 29: S1542-3565(20)30752-7. doi: 10.1016/j.cgh.2020.05.045.Massironi S., Vigano C., Dioscoridi L. et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol. -2020 May 29: S1542-3565(20)30752-7. doi: 10.1016/j.cgh.2020.05.045.Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. - 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018.Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. - 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018.Toskes P. Bacterial overgrowth of the gastrointestinal tract // Adv. Int. Med. 1993. Vol. 38. P. 387-407Toskes P. Bacterial overgrowth of the gastrointestinal tract // Adv. Int. Med. 1993. Vol. 38. P. 387-407Маев И. В., Кучерявый Ю. А., Андреев Д. Н., Ивашкина Н. Ю. Синдром избыточного бактериального роста в тонкой кишке: клиническое значение, критерии диагностики и терапевтическая тактика. Инфекционные болезни: новости, мнения, обучение. - 2016. - № 3. - С. 118-125Maev I. V., Kucheryavyy Yu. A., Andreev D. N., Ivashkina N. Yu. Small bowel bacterial overgrowth syndrome: clinical relevance, criteria of diagnostics and therapeutic management. Infectious diseases: News, Opinions, Training. 2016, no. 3, pp. 118-125.Lauritano E. C., Gabrielli M., Lupascu A. et al. Rifaximin dosefinding study for the treatment of small intestinal bacterial overgrowth // Aliment. Pharmacol. Ther. - 2005. - Vol. 22. - P. 31-35.Lauritano E. C., Gabrielli M., Lupascu A. et al. Rifaximin dosefinding study for the treatment of small intestinal bacterial overgrowth // Aliment. Pharmacol. Ther. - 2005. - Vol. 22. - P. 31-35.Cuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin // Minerva Gastroenterol. Dietol. - 2006. - Vol. 52. - P. 89-95.Cuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin // Minerva Gastroenterol. Dietol. - 2006. - Vol. 52. - P. 89-95.Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055.Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055.Pan L., Mu M., Ren H. G. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. - 2020. DOI: 10.14309/ajg.0000000000000620.Pan L., Mu M., Ren H. G. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. - 2020. DOI: 10.14309/ajg.0000000000000620.Ивашкин В. Т. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журнгастроэнтеролгепатолколопроктол. - 2017. - Т. 27(5). - С. 76-93. DOI: 10.22416/1382-4376-2017-27-5-76-93.Ivashkin V. T., Shelygin Yu. A., Baranskaya Y. K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-76-93Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. Published 2020 Mar 6. doi:10.3390/ijerph17051729Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. Published 2020 Mar 6. doi:10.3390/ijerph17051729Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert RevGastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70. DOI:10.1586/egh.10.25.38-41Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert RevGastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70. DOI:10.1586/egh.10.25.38-41Zhou Q., Verne M. L., Fields J. Z. et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002.Zhou Q., Verne M. L., Fields J. Z. et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002.Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70.Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. - 2010. - Vol. 4(3). - P. 261-70.Song D. U., Ryu M. H., Chay K. O. et al. Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-52.Song D. U., Ryu M. H., Chay K. O. et al. Effect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-52.Suzuki T., Yoshida N., Nakabe N. et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77.Suzuki T., Yoshida N., Nakabe N. et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77.Парфенов А. И., Быкова С. В., Сабельникова Е. А. идр. Энтеропатия с нарушенным перевариванием мембран и ребамипидом. Консилиум Медикум. -2019. - Т. 21 (8). -С. 49-57. DOI: 10.26442/20751753.2019.8.190504Parfenov A.I., Bykova S.V., Sabelnikova E.A. et al. Enteropathy with impaired membrane digestion and rebamipide. Consilium Medicum. 2019; 21 (8): 49-57. DOI: 10.26442/20751753.2019.8.190504Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A CrossSectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019;25(6):623-636.Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A CrossSectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019;25(6):623-636.Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. - 2019. Jun 26: e13385. doi: 10.1111/ijcp.13385.Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. - 2019. Jun 26: e13385. doi: 10.1111/ijcp.13385.Menees S. B., Maneerattannaporn M., Kim H. M., Chey W. D. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012 Jan; 107(1):28-35Menees S. B., Maneerattannaporn M., Kim H. M., Chey W. D. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012 Jan; 107(1):28-35Anand S., Mande S. S. Diet, Microbiota and Gut-Lung Connection. Front Microbiol. 2018;(9):2147. doi: 10.3389/fmicb.2018.02147.Anand S., Mande S. S. Diet, Microbiota and Gut-Lung Connection. Front Microbiol. 2018;(9):2147. doi: 10.3389/fmicb.2018.02147.Trompette A., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014;20 (2):159-166.Trompette A., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014;20 (2):159-166.Samuelson D. R., Welsh D. A., Shellito J. E. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015. 2015;(6):1085.. doi: 10.3389/fmicb.2015.01085.Samuelson D. R., Welsh D. A., Shellito J. E. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015. 2015;(6):1085.. doi: 10.3389/fmicb.2015.01085.Nikolaou E., Kamilari E., Savkov D. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. World J Pediatr. 2020;16(2):168-176. doi: 10.1007/s12519-019-00315-6.Nikolaou E., Kamilari E., Savkov D. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. World J Pediatr. 2020;16(2):168-176. doi: 10.1007/s12519-019-00315-6.Pinto-Cardoso S., Klatt N. R., Reyes-Teran G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. CurrOpin HIV AIDS. 2018;13(1):53-60. doi: 10.1097/COH.0000000000000428.Pinto-Cardoso S., Klatt N. R., Reyes-Teran G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. CurrOpin HIV AIDS. 2018;13(1):53-60. doi: 10.1097/COH.0000000000000428.Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571-575. doi: 10.4161/gmic.32130.Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571-575. doi: 10.4161/gmic.32130.Otani K., Tanigawa T., Watanabe T. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 2017;95:22-28. doi: 10.1159/000452356Otani K., Tanigawa T., Watanabe T. et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 2017;95:22-28. doi: 10.1159/000452356Jang H., Park S., Lee J. et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018;33(4):878-886. doi:10.1111/jgh.14021Jang H., Park S., Lee J. et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018;33(4):878-886. doi:10.1111/jgh.14021Rahier J. F., Magro F., Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;(8):443-468.Rahier J. F., Magro F., Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;(8):443-468.Al-Ani A. H., Prentice R. E., Rentsch C. A. et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment PharmacolTher. -2020. - Apr 29:10.1111/apt.15779. Doi: 10.1111/apt.15779.Al-Ani A. H., Prentice R. E., Rentsch C. A. et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment PharmacolTher. -2020. - Apr 29:10.1111/apt.15779. Doi: 10.1111/apt.15779.Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 20, 2020Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 20, 2020Ивашкин В. Т., Шелыгин Ю. А. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология, 2017. - № 1(59). - С. 6-30.V. Ivashkin, Yu. Shelygin, I. Khalif, et al. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017;(1):6-30. (In Russ.)Samanta J., Dhar J., Khaliq A., Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-18. DOI: 10.1055/s-0040-1712077Samanta J., Dhar J., Khaliq A., Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-18. DOI: 10.1055/s-0040-1712077Kennedy N. A., Jones G. R., Lamb C. A., et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. doi:10.1136/gut-jnl-2020-321244Kennedy N. A., Jones G. R., Lamb C. A., et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. doi:10.1136/gut-jnl-2020-321244Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic American Gastroenterological Association. https://gastro.org/practice-guidance/practice-updates/covid-19/gastroenterology-professional-society-guidance-on-en-doscopic-procedures-during-the-covid-19-pandemic/ Accessed June 06, 2020.Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic American Gastroenterological Association. https://gastro.org/practice-guidance/practice-updates/covid-19/gastroenterology-professional-society-guidance-on-en-doscopic-procedures-during-the-covid-19-pandemic/ Accessed June 06, 2020.Rubin D. T., Abreu M. T., Rai V., Siegel C. A. On behalf of the International Organization for the Study of Inflammatory Bowel Disease, Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. - 2020, doi: https://doi.org/10.1053/j.gastro.2020.04.002.Rubin D. T., Abreu M. T., Rai V., Siegel C. A. On behalf of the International Organization for the Study of Inflammatory Bowel Disease, Management of Patients with Crohn's Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. - 2020, doi: https://doi.org/10.1053/j.gastro.2020.04.002.RAND PANEL STATEMENTS Patients with COVID-19 Crohn's Disease and COVID-19 Ulcerative Colitis. IOIBD Update on COVID19 for Patients with Crohn's Disease and Ulcerative Colitis https://ioibd.org/wp-content/uploads/2020/05/RAND-PANEL-STATEMENTS.pdfRAND PANEL STATEMENTS Patients with COVID-19 Crohn's Disease and COVID-19 Ulcerative Colitis. IOIBD Update on COVID19 for Patients with Crohn's Disease and Ulcerative Colitis https://ioibd.org/wp-content/uploads/2020/05/RAND-PANEL-STATEMENTS.pdfВременные рекомендации по ведению больных COVID-19 и эндокринными заболеваниями / Под ред. Гринева Е. Н., Халимова Ю. Ш., Бабенко А. Ю. и др. - Медицинской Ассоциацией Эндокринологов Санкт-Петербурга, 2020 г. - 9 с.Grinev E. N., Halimov Yu. Sh., Babenko A. Yu., et al. Temporary guidelines for the management of patients with COVID-19 and endocrine diseases. Medical Association of Endocrinologists. St. Petersburg, 2020. 9 P.Ивашкин В. Т., Шептулин А. А., Зольникова О. Ю. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения // Российский журнал гастроэнтерологии, гепатологии и колопроктоло-гии 2020 30(2) - 7 https: //doi.org/10.22416/138243712020-30-3-7.Ivashkin V. T., Sheptulin A. A., Zolnikova O. Yu., Okhlobystin A. V., Poluektova E. A., Trukhmanov A. S., Shirokova E. N., Gonik M. I., Trofi mivskaya N. I. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7-13. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-3-7Szatmary P., Arora A., Raraty M. G. T. et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. - 2020. doi.org/10.1053/j.gastro.2020.05.069.Szatmary P., Arora A., Raraty M. G. T. et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. - 2020. doi.org/10.1053/j.gastro.2020.05.069.Bruno G., Fabrizio C., Santoro C. R., Buccoliero G. B. Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence [published online ahead of print, 2020 Jun 4]. J Med Virol. -2020;10.1002/jmv.26134. doi:10.1002/jmv.26134Bruno G., Fabrizio C., Santoro C. R., Buccoliero G. B. Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence [published online ahead of print, 2020 Jun 4]. J Med Virol. -2020;10.1002/jmv.26134. doi:10.1002/jmv.26134Временные методические рекомендации. Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19) // Драпкина О. М., Маев И. В., Бакулин И. Г. и др. -Москва, 2020. - 68 с.Drapkina O. M., Maev I. V., Bakulin I. G. et al. Temporary guidelines. Diseases of the digestive system in the context of the novel coronavirus infection (COVID-19) pandemic. Moscow, 2020. 68 p.Клинические Рекомендации Российского Общества Хирургов, Ассоциации гепатопанкреатобилиарных хирургов стран СНГ «Острый панкреатит» - М., 2015. - 38 с.Clinical Recommendations of the Russian Society of Surgeons, the Association of Hepatopancreatobiliary Surgeons of the CIS countries “Acute Pancreatitis”. Moscow, 2015. 38 p.Рекомендации Научного Общества Гастроэнтерологов по диагностике и лечению хронического панкреатита (приняты Псъездом НОГР 2 марта 2011 на заседании Российского панкреатологического клуба// Экспериментальная и клиническая медицина. - 2011. - № 7. - С. 122-129.Recommendations of the Scientific Society of Gastroenterologists for the diagnosis and treatment of chronic pancreatitis (adopted by the II Congress of the NOGR on March 2, 2011 at the meeting of the Russian Pancreatological Club. Experimental and Clinical Medicine. 2011;(7): 122-129.Российский консенсус по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Абдулхаков С. Р. и соавт.// Терапевтический архив. - 2017. - № 2. - С. 105-113. doi: 10.17116/terarkh2017892105-113.Khatkov IE, Maev IV, Abdulkhakov SR, et al. The Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic archive = Terapevticheskiy arkhiv. 2017;89(2):105-113. https://doi.org/10.17116/terarkh2017892105-113Хатьков И. Е. Спорные вопросы российского консенсуса по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А., Гриневич В. Б. //Альманах клинической медицины. - 2016. -Т. 44., № 6. - С. 654-660.Khat'kov I. E., Maev I. V., Bordin D. S., Kucheryavyy Yu. A., Grinevich V. B. The Russian consensus on diagnosis and treatment of chronic pancreatitis: points of debate. Almanac of Clinical Medicine. 2016;44(6):654-660. (In Russ.) https://doi.org/10.18786/2072-0505-2016-44-6-654-660Ивашкин В. Т., Маев И. В., Охлобыстин А. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72-100.Ivashkin V. T., Mayev I. V., Okhlobystin A. V., et al. Diagnostics and treatment of pancreatic exocrine insufficiency: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):72-100. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-2-72-100Клинические Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению хронического панкреатита / Под ред. Ивашкина В. Т., Маева И. В., Шифрина О. С. и др. - М., 2014. -45с.Ivashkin VT, Mayev IV, Shifrin OS, et al. Clinical Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis. Moscow, 2014. 45p.Хатьков И. Е. Российский консенсус по диагностике и лечению хронического панкреатита: акцент на нутритивный статус и вопросы питания. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А. и соавт.// Фарматека. - 2016; Гастроэнтерология/гепатология. - С. 27-32.Khatkov I. E., Mayev I. V., Bordin D. S., et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: focus on nutritional status and problems of nutrition. Farmateka. 2016; s5-16:27-32 .Клинические Рекомендации Российской Ассоциации Эндокринологов «Алгоритмы Специализированной Медицинской Помощи больным Сахарным Диабетом» / Под ред. Дедова И. И., Шестаковой М. В., Майрова А. Ю. - М., 2017. - 111 с.Dedov I. I., Shestakova M. V., Mayrov A. Yu. Clinical Recommendations of the Russian Association of Endocrinologists “Algorithms of Specialized Medical Care for Patients with Diabetes Mellitus”. Moscow, 2017. 111 P.В. Т. Ивашкин, И. В. Маев, П. В. Царьков и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по Диагностике и лечению язвенной болезни у взрослых. 2020Ivashkin V. T., Maev I. V., Tsar'kov P. V., et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of peptic ulcer disease in adults. 2020Diaz J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3): taaa041. doi:10.1093/jtm/taaa041.Diaz J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3): taaa041. doi:10.1093/jtm/taaa041.Zheng Y. Y., Ma Y. T., Zhang J. Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5.Zheng Y. Y., Ma Y. T., Zhang J. Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5.Abassi Z., Assady S., Khoury E. E., Heyman S. N. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. Am J Physiol Heart Circ Physiol. 2020; 318(5): H1080-H1083. doi:10.1152/ajpheart.00215.2020.Abassi Z., Assady S., Khoury E. E., Heyman S. N. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. Am J Physiol Heart Circ Physiol. 2020; 318(5): H1080-H1083. doi:10.1152/ajpheart.00215.2020.Vaduganathan M., Vardeny O., Michel T., McMurray J. V, Pfeffer M. A, Solomon S. D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760.Vaduganathan M., Vardeny O., Michel T., McMurray J. V, Pfeffer M. A, Solomon S. D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760.Gheblawi M., Wang K., Viveiros A., et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015.Gheblawi M., Wang K., Viveiros A., et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474. doi:10.1161/CIRCRESAHA.120.317015.South A. M., Diz D. I., Chappell M. C. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084-H1090. doi:10.1152/ajpheart.00217.2020.South A. M., Diz D. I., Chappell M. C. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084-H1090. doi:10.1152/ajpheart.00217.2020.Ferrario C. M, Jessup J., Chappell M. C. et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-10.Ferrario C. M, Jessup J., Chappell M. C. et al. Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605-10.Burchill L. J, Velkoska E., Dean R.G, Griggs K., Patel S. K., Burrell L. M. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-58.Burchill L. J, Velkoska E., Dean R.G, Griggs K., Patel S. K., Burrell L. M. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 2012; 123: 649-58.Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensinconverting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28: 15-21.Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensinconverting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28: 15-21.Halliday B. P., Wassall R., Lota A. S., et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393: 61-73.Halliday B. P., Wassall R., Lota A. S., et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393: 61-73.Mehta N., Kalra A, Nowacki A. S., et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; e201855. doi:10.1001/jamacardio.2020.1855.Mehta N., Kalra A, Nowacki A. S., et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; e201855. doi:10.1001/jamacardio.2020.1855.Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; doi:10.1056/NEJMoa2006923.Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020; doi:10.1056/NEJMoa2006923.Tadic M., Cuspid C., Mancia G., Dell'Oro R., Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacological research, vol. 158 104906. 13 May. 2020, doi:10.1016/j.phrs.2020.104906.Tadic M., Cuspid C., Mancia G., Dell'Oro R., Grassi G. COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Pharmacological research, vol. 158 104906. 13 May. 2020, doi:10.1016/j.phrs.2020.104906.Jeffrey K. Aronson, Robin E. Ferner. Drugs and the renin-angiotensin system in covid-19. Clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. BMJ 2020;369: m1313 doi: 10.1136/bmj.m1313 (Published 2 April 2020) Page 2.Jeffrey K. Aronson, Robin E. Ferner. Drugs and the renin-angiotensin system in covid-19. Clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. BMJ 2020;369: m1313 doi: 10.1136/bmj.m1313 (Published 2 April 2020) Page 2.Aronson J. K., Ferner R. E., с Drugs and the renin-angiotensin system in covid-19. BMJ. 2020;369: m1313. Published 2020 Apr 2. doi:10.1136/bmj.m1313Aronson J. K., Ferner R. E., с Drugs and the renin-angiotensin system in covid-19. BMJ. 2020;369: m1313. Published 2020 Apr 2. doi:10.1136/bmj.m1313Wang T. D. Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators. Acta Cardiol Sin. 2020;36(3):179-182. doi:10.6515/ACS.202005_36(3).20200430A.Wang T. D. Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators. Acta Cardiol Sin. 2020;36(3):179-182. doi:10.6515/ACS.202005_36(3).20200430A.Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика // 2019;18(1):5-66 http://dx.doi.org/10.15829/1728-8800-2019-1-5-66Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) https://doi.org/10.15829/1728-8800-2019-1-5-66Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? Journal of Hypertension. 2019;(37):1574-1586. DOI:10.1097/HJH.0000000000002088.Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? Journal of Hypertension. 2019;(37):1574-1586. DOI:10.1097/HJH.0000000000002088.Wade D. T. Rehabilitation after COVID-19: an evidence-based approach [published online ahead of print, 2020 Jun 9]. Clin Med (Lond). 2020; clinmed.2020-0353. doi:10.7861/clinmed.2020-0353]. De Biase S,Wade D. T. Rehabilitation after COVID-19: an evidence-based approach [published online ahead of print, 2020 Jun 9]. Clin Med (Lond). 2020; clinmed.2020-0353. doi:10.7861/clinmed.2020-0353]. De Biase S,Cook L, Skelton D. A., Witham M, Ten Hove R. The COVID-19 Rehabilitation Pandemic [published online ahead of print, 2020 May 29]. Age Ageing. 2020; afaa118. doi:10.1093/ageing/afaa118Cook L, Skelton D. A., Witham M, Ten Hove R. The COVID-19 Rehabilitation Pandemic [published online ahead of print, 2020 May 29]. Age Ageing. 2020; afaa118. doi:10.1093/ageing/afaa118Lopez M., Bell K., Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Non-Pulmonary Manifestations and Complications [published online ahead of print, 2020 May 26]. Am J Phys Med Rehabil. 2020;doi:10.1097/PHM.0000000000001479Lopez M., Bell K., Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Non-Pulmonary Manifestations and Complications [published online ahead of print, 2020 May 26]. Am J Phys Med Rehabil. 2020; doi:10.1097/PHM.0000000000001479Wang F., Wang H., Fan J. et al. Pancreatic injury patterns in patients with COVID-19 pneumonia [published online ahead of print, 2020 Apr 1]. Gastroenterology. 2020;. doi:10.1053/j.gastro.2020.03.055Wang F., Wang H., Fan J. et al. Pancreatic injury patterns in patients with COVID-19 pneumonia [published online ahead of print, 2020 Apr 1]. Gastroenterology. 2020;. doi:10.1053/j.gastro.2020.03.055Han C., Duan C., Zhang S. et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes [published online ahead of print, 2020 Apr 15]. Am J Gastroenterol. 2020; doi:10.14309/ajg.0000000000000664Han C., Duan C., Zhang S. et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes [published online ahead of print, 2020 Apr 15]. Am J Gastroenterol. 2020; doi:10.14309/ajg.0000000000000664Ling Y., Xu S. B., Lin Y. X. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients [published online ahead of print, 2020 Feb 28]. Chin Med J (Engl). 2020; doi:10.1097/CM9.0000000000000774Ling Y., Xu S. B., Lin Y. X. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients [published online ahead of print, 2020 Feb 28]. Chin Med J (Engl). 2020; doi:10.1097/CM9.0000000000000774Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment PharmacolTher. 2020;51(9):843-851. doi:10.1111/apt.15731Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment PharmacolTher. 2020;51(9):843-851. doi:10.1111/apt.15731Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J ChinMedAssoc. 2020;83(6):521-523. doi:10.1097/JCMA.0000000000000319Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J ChinMedAssoc. 2020;83(6):521-523. doi:10.1097/JCMA.0000000000000319Thachil J et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. published: 25 March 25, 2020Th achil J et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. published: 25 March 25, 2020Hunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020 https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdfHunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020 https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdfGris J. C. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. https://doi.org/10.1016/j.accpm.2020.04.013Gris J. C. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. https://doi.org/10.1016/j.accpm.2020.04.013Wade D. T. What is rehabilitation? An empirical investigation leading to an evidence-based description. Clin Rehabil. 2020;34(5):571-583. doi:10.1177/0269215520905112Wade D. T. What is rehabilitation? An empirical investigation leading to an evidence-based description. Clin Rehabil. 2020;34(5):571-583. doi:10.1177/0269215520905112Infusino F., Marazzato M., Mancone M. et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020;12(6):E.1718. Published 2020 Jun 8. doi:10.3390/nu12061718Infusino F., Marazzato M., Mancone M. et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020;12(6):E.1718. Published 2020 Jun 8. doi:10.3390/nu12061718Крюков, А. Е. Особенности кишечного микробиоценоза у лиц молодого возраста с внебольничной пневмонией: автореф. дис. ... канд. мед. наук: 14.00.05 / Крюков Александр Евгеньевич. - СПб., 2006. - 27 с.Kryukov A. E. [Features of intestinal microbiocenosis in young people with community-acquired pneumonia]. Cand. Med. Sciences: 14.00.05. SPb., 2006. 27 p.Almario C. V., Chey W. D., Spiegel B. M. R. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. - 2020 (pre-print posted online July 7, 2020)Almario C. V., Chey W. D., Spiegel B. M. R. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. - 2020 (preprint posted online July 7, 2020)Camilleri M., Oduyebo I., Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unansweredquestions. Am J Physiol Gastrointest Liver Physiol.2016;311(5):777-784. doi: 10,.1152/ajpgi.00242.2016.Camilleri M., Oduyebo I., Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unansweredquestions. Am J Physiol Gastrointest Liver Physiol.2016;311(5):777-784. doi: 10,.1152/ajpgi.00242.2016.Ng Q. X., Soh A. Y. S., Loke W., Lim D. Y., Yeo W. S. The role of inflammation inirritable bowel syndrome (IBS).J Inflamm Res.2018;11:345 doi:10.214/JIR.S174982.Ng Q. X., Soh A. Y. S., Loke W., Lim D. Y., Yeo W. S. The role of inflammation inirritable bowel syndrome (IBS). J Inflamm Res.2018;11:345 doi:10.214/JIR.S174982.Самсонов А. А., Андреев Д. Н., Дичева Д. Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека.2014;(18):7-14. Режим доступа: https://www.elibrary.ru/item.asp?id=22474321.Samsonov A. A., Andreev D. N., Dicheva D. T. Irritable bowel syndrome from the point of view of modern gastroenterology. Farmateka. 2014;18 (291):7-14.Christopher H. Blevins et al. The Esophageal Epithelial Barrier in Health and Disease Clinical Gastroenterology and Hepatology 2018;16:608-617 https://doi.org/10.1016/j.cgh.2017.06.035Christopher H. Blevins et al. The Esophageal Epithelial Barrier in Health and Disease Clinical Gastroenterology and Hepatology 2018;16:608-617 https://doi.org/10.1016/j.cgh.2017.06.035В. Т. Ивашкин, А. С. Трухманов, М. И. Гоник. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни ТЕРАПЕВТИЧЕСКИЙ АРХИВ 4, 2020 DOI:10.26442/00403660.2020.04.000568Ivashkin VT, Trukhmanov AS, Gonik MI. Ter Arkh. 2020;92(4):98-104. Published 2020 May 19. doi:10.26442/00403660.2020.04.000568Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Reflux Disease, Including Non-Erosive Reflux Disease: A Multi-Center, Randomized, Single-Blind, Placebo-Controlled Study AGA Abstracts May 2019 Volume 156, Issue 6, Supplement 1, Page S-5Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Reflux Disease, Including Non-Erosive Reflux Disease: A Multi-Center, Randomized, Single-Blind, Placebo-Controlled Study AGA Abstracts May 2019Volume 156, Issue 6, Supplement 1, Page S-5SuJin Hong et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study Gut Liver. 2016 Nov; 10(6): 910-916.SuJin Hong et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study Gut Liver. 2016 Nov; 10(6): 910-916.Gweon T. G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50.Gweon T. G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50.Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015;17(6):24. doi:10.1007/s11894-015-0452-2Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015;17(6):24. doi:10.1007/s11894-015-0452-2Yu. M. Stepanov et al. Determination of intercellular contacts in patients with irritable bowel syndrome Gastroenterologia. 2019;53(2):128-131. doi: 10.22141/2308-2097.53.2.2019.168987Yu. M. Stepanov et al. Determination of intercellular contacts in patients with irritable bowel syndrome Gastroenterologia. 2019;53(2):128-131. doi: 10.22141/2308-2097.53.2.2019.168987Fukui H.: Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? InflammIntest Dis 2016;1:135-145. doi: 10.1159/000447252Fukui H.: Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? InflammIntest Dis 2016;1:135-145. doi: 10.1159/000447252Л. Б. Лазебник, Е. В. Голованова, проф. С. А. Алексеенко и др. Российский консенсус «Гипераммониемии у взрослых» Утвержден в качестве документа Российского научного медицинского общества терапевтов (РНМОТ) и Научного общества гастроэнтерологов России (НОГР) 20-21 ноября 2019 г. XIV Национальным конгрессом терапевтов и XXII съездом НОГР. Терапия, 2020, № 4, 26-51 DOI: https://dx.doi.org/10.18565/therapy.2020.4.36-51Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Russian consensus “Hyperammonemia in adults”. THERAPY. 2020;(4):36-51. DOI: https://dx.doi.org/10.18565/therapy.2020.4.36-51Максимов В. А., Торшин И. Ю., Чучалин А. Г. и др. Эффективность и безопасность полипептидного препарата (лаеннек) в терапии COVID-19, Экспериментальная и клиническая гастроэнтерология. 2020, 6 (178) 55-63 DOI: 10.31146/1682-8658-ecg-178-6-55-63Maksimov V. A., Torshin I. Yu., Chuchalin A. G., et al. The effectiveness and safety of a polypeptide drug (Laennec) for the treatment of COVID-19. Experimental and Clinical Gastroenterology. 2020;(6):55-63. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-178-6-55-63Saigal S. et al. Применение адеметионина у пациентов с заболеваниями печени: обзор Int J Res Med Sci. 2019 Jun;7(6):2482-2493, DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192550Saigal S. et al. Применение адеметионина у пациентов с заболеваниями печени: обзор Int J Res Med Sci. 2019 Jun;7(6):2482-2493, DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192550Openshaw P. J. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100-102. doi: 10.1038/mi.2008.79.Openshaw P. J. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100-102. doi: 10.1038/mi.2008.79.Zuo T, Zhang F, Lui GCY, Yeoh YK, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 May 19: S0016-5085(20)34701-6. doi: 10.1053/j.gastro.2020.05.048.Zuo T, Zhang F, Lui GCY, Yeoh YK, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 May 19: S0016-5085(20)34701-6. doi: 10.1053/j.gastro.2020.05.048.Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza. Clin Infect Dis. 2020 Jun 4: ciaa709. doi: 10.1093/cid/ciaa709.Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Influenza. Clin Infect Dis. 2020 Jun 4: ciaa709. doi: 10.1093/cid/ciaa709.Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. 2020 May 13;285:198018. doi: 10.1016/j.virusres.2020.198018.Dhar D., Mohanty A. Gut microbiota and Covid-19-possible link and implications. Virus Res. 2020 May 13;285:198018. doi: 10.1016/j.virusres.2020.198018.Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieёrs G, Guery B, Delhaes L. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and InterKingdom Crosstalks. Front Cell Infect Microbiol. 2020 Feb 19;10:9. doi: 10.3389/fcimb.2020.00009.Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieёrs G, Guery B, Delhaes L. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and InterKingdom Crosstalks. Front Cell Infect Microbiol. 2020 Feb 19;10:9. doi: 10.3389/fcimb.2020.00009.Tang L, Gu S, Gong Y, Li B, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. doi: 10.1016/j.eng.2020.05.013.Tang L, Gu S, Gong Y, Li B, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. doi: 10.1016/j.eng.2020.05.013.Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. doi: 10.1164/rc-cm.200912-1853OC.Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. doi: 10.1164/rc-cm.200912-1853OC.Zeng J, Wang CT, Zhang FS, Qi F, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016 Jun;42(6):1018-28. doi: 10.1007/s00134-016-4303-x.Zeng J, Wang CT, Zhang FS, Qi F, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016 Jun;42(6):1018-28. doi: 10.1007/s00134-016-4303-x.Di Renzo L, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4062-4063. doi: 10.26355/eur-rev_202004_20977.Di Renzo L, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4062-4063. doi: 10.26355/eur-rev_202004_20977.Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health. 2020 May 8;8:186. doi: 10.3389/fpubh.2020.00186.Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health. 2020 May 8;8:186. doi: 10.3389/fpubh.2020.00186.Sarkar P, Borah S, Sharma HK. Can microbial SCFA, Butyrate be the alternate Savior against COVID-19?, Curr. Trends Pharm. Res., 2020, 7 (1): 11-14.Sarkar P, Borah S, Sharma HK. Can microbial SCFA, Butyrate be the alternate Savior against COVID-19?, Curr. Trends Pharm. Res., 2020, 7 (1): 11-14.d'Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020 Jul 7;7:389. doi: 10.3389/fmed.2020.00389.d'Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020 Jul 7;7:389. doi: 10.3389/fmed.2020.00389.He LH, Ren LF, Li JF, Wu YN, Li X, Zhang L. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Front Microbiol. 2020 Jun 9;11:1388. doi: 10.3389/fmicb.2020.01388.He LH, Ren LF, Li JF, Wu YN, Li X, Zhang L. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Front Microbiol. 2020 Jun 9;11:1388. doi: 10.3389/fmicb.2020.01388.Saville S., Ouwehand A. Immune Impacts of Probiotics, Prebiotics and Synbiotics. International Probiotics Association (IPA) Education and Communications Committee. Available at: http://internationalprobiotics.org/immune/ [Accessed 10 August 2020].Saville S., Ouwehand A. Immune Impacts of Probiotics, Prebiotics and Synbiotics. International Probiotics Association (IPA) Education and Communications Committee. Available at: http://internationalprobiotics.org/immune/ [Accessed 10 August 2020].ISAPP board of directors. How some probiotic scientists are working to address COVID-19. Available at: https://isappscience.org/how-some-probiotic-and-prebiotic-scientists-are-working-to-address-covid-19/ [Accessed 10 August 2020].ISAPP board of directors. How some probiotic scientists are working to address COVID-19. Available at: https://isappscience.org/how-some-probiotic-and-prebiotic-scientists-are-working-to-address-covid-19/ [Accessed 10 August 2020].Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-8716. doi: 10.3748/wjg.v20.i26.8709.Lorenzo-Zuniga V, Llop E, Suarez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-8716. doi: 10.3748/wjg.v20.i26.8709.Белова Г. В. Рекомендации по эндоскопии и клинической практике в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2020;(5):4-7. DOI: 10.31146/1682-8658-ecg-177-5-4-7Belova G. V. Recommendations for endoscopy and clinical practice in gastroenterology. Experimental and Clinical Gastroenterology. 2020;(5):4-7. (In Russ.) DOI: 10.31146/1682-8658-ecg-177-5-4-7Парфенов А. И., Ручкина И. Н., Атауллаханов Р. И., Белая О. Ф., Чикунова Б. З., Пичугин А. В., Кожемякина Е. Ш. Постинфекционный синдром раздраженного кишечника. Терапевтический архив 2009; 81(2): 39-45.Parfenov AI, Ruchkina IN, Ataullakhanov RI, Belaia OF, Chikunova BZ, Pichugin AV, Kozhemiakina ESh. Postinfection irritable bowel syndrome. Ter Arkh. 2009;81(2): 39-45. (In Russ.)Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med (Lausanne). 2020 Jun 5;7:292. doi: 10.3389/fmed.2020.00292.Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med (Lausanne). 2020 Jun 5;7:292. doi: 10.3389/fmed.2020.00292.

The authors declare that there are no conflicts of interest present.